[{"id":"111c1a17-fe9b-4de2-8802-129cd4e4d500","acronym":"LEAP-006","url":"https://clinicaltrials.gov/study/NCT03829319","created_at":"2021-01-17T17:11:51.730Z","updated_at":"2025-02-25T13:35:12.715Z","phase":"Phase 3","brief_title":"Safety and Efficacy Study of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-7902-006/E7080-G000-315/LEAP-006)","source_id_and_acronym":"NCT03829319 - LEAP-006","lead_sponsor":"Merck Sharp \u0026 Dohme LLC","biomarkers":" EGFR • ALK • ROS1","pipe":"","alterations":" ","tags":["EGFR • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cisplatin • carboplatin • Lenvima (lenvatinib) • pemetrexed"],"overall_status":"Completed","enrollment":" Enrollment 761","initiation":"Initiation: 03/25/2019","start_date":" 03/25/2019","primary_txt":" Primary completion: 08/11/2023","primary_completion_date":" 08/11/2023","study_txt":" Completion: 08/30/2024","study_completion_date":" 08/30/2024","last_update_posted":"2025-02-21"},{"id":"8100f49e-ecbc-41b2-9130-5ed625da8fc7","acronym":"","url":"https://clinicaltrials.gov/study/NCT04669496","created_at":"2025-02-25T13:40:17.235Z","updated_at":"2025-02-25T13:40:17.235Z","phase":"Phase 2/3","brief_title":"Phase II-III Clinical Trial of PD1 Antibody (Toripalimab), Lenvatinib and GEMOX Neoadjuvant Treatment for Resectable Intrahepatic Cholangiocarcinoma with High-risk Recurrence Factors","source_id_and_acronym":"NCT04669496","lead_sponsor":"Shanghai Zhongshan Hospital","biomarkers":" TMB • MSI • CEACAM5 • MUC16","pipe":" | ","alterations":" PD-L1 expression","tags":["TMB • MSI • CEACAM5 • MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lenvima (lenvatinib) • Loqtorzi (toripalimab-tpzi) • oxaliplatin"],"overall_status":"Recruiting","enrollment":" Enrollment 178","initiation":"Initiation: 01/20/2021","start_date":" 01/20/2021","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2025-02-21"},{"id":"8fdc7448-fd08-4efe-a0dd-3b2c163d7e37","acronym":"LIBRETTO-432","url":"https://clinicaltrials.gov/study/NCT04819100","created_at":"2021-03-26T14:52:36.044Z","updated_at":"2025-02-25T13:40:25.498Z","phase":"Phase 3","brief_title":"A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)","source_id_and_acronym":"NCT04819100 - LIBRETTO-432","lead_sponsor":"Eli Lilly and Company","biomarkers":" RET","pipe":" | ","alterations":" RET fusion","tags":["RET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RET fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Retevmo (selpercatinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 170","initiation":"Initiation: 12/20/2021","start_date":" 12/20/2021","primary_txt":" Primary completion: 05/01/2027","primary_completion_date":" 05/01/2027","study_txt":" Completion: 08/01/2032","study_completion_date":" 08/01/2032","last_update_posted":"2025-02-21"},{"id":"63b7f842-7dbd-4050-9b6c-f6c0d81db8df","acronym":"(MARGARET)","url":"https://clinicaltrials.gov/study/NCT04683250","created_at":"2021-01-19T20:47:05.192Z","updated_at":"2025-02-25T14:02:08.938Z","phase":"Phase 1/2","brief_title":"Study of RET Inhibitor TAS0953/HM06 in Patients with Advanced Solid Tumors with RET Gene Abnormalities","source_id_and_acronym":"NCT04683250 - (MARGARET)","lead_sponsor":"Taiho Pharmaceutical Co., Ltd.","biomarkers":" RET","pipe":" | ","alterations":" RET fusion","tags":["RET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RET fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e vepafestinib (TAS0953/HM06)"],"overall_status":"Recruiting","enrollment":" Enrollment 202","initiation":"Initiation: 12/16/2020","start_date":" 12/16/2020","primary_txt":" Primary completion: 03/01/2030","primary_completion_date":" 03/01/2030","study_txt":" Completion: 03/01/2031","study_completion_date":" 03/01/2031","last_update_posted":"2025-02-14"},{"id":"e11728e3-5408-43ee-84fa-396a29b7eccd","acronym":"LEAP-007","url":"https://clinicaltrials.gov/study/NCT03829332","created_at":"2021-01-18T18:54:37.440Z","updated_at":"2025-02-25T13:35:13.317Z","phase":"Phase 3","brief_title":"Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naïve Nonsmall Cell Lung Cancer (NSCLC) (MK-7902-007/E7080-G000-314/LEAP-007)","source_id_and_acronym":"NCT03829332 - LEAP-007","lead_sponsor":"Merck Sharp \u0026 Dohme LLC","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Lenvima (lenvatinib)"],"overall_status":"Completed","enrollment":" Enrollment 623","initiation":"Initiation: 03/13/2019","start_date":" 03/13/2019","primary_txt":" Primary completion: 05/19/2021","primary_completion_date":" 05/19/2021","study_txt":" Completion: 04/24/2024","study_completion_date":" 04/24/2024","last_update_posted":"2025-02-14"},{"id":"231092fb-00ef-4553-bd1a-e401bd09459d","acronym":"LITESPARK-016","url":"https://clinicaltrials.gov/study/NCT04976634","created_at":"2021-07-26T17:53:23.648Z","updated_at":"2025-02-25T15:19:12.763Z","phase":"Phase 2","brief_title":"Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016)","source_id_and_acronym":"NCT04976634 - LITESPARK-016","lead_sponsor":"Merck Sharp \u0026 Dohme LLC","biomarkers":" MSI","pipe":"","alterations":" ","tags":["MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Lenvima (lenvatinib) • Welireg (belzutifan)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 730","initiation":"Initiation: 08/18/2021","start_date":" 08/18/2021","primary_txt":" Primary completion: 03/22/2027","primary_completion_date":" 03/22/2027","study_txt":" Completion: 03/22/2027","study_completion_date":" 03/22/2027","last_update_posted":"2025-02-12"},{"id":"a46eecea-cdfb-4325-ac71-c96ea8e37386","acronym":"","url":"https://clinicaltrials.gov/study/NCT05823311","created_at":"2023-04-21T15:04:25.336Z","updated_at":"2025-02-25T15:20:26.716Z","phase":"Phase 3","brief_title":"Lenvatinib, Tislelizumab Combined with Gemcitabine and Cisplatin (GPLET) in the Treatment of Advanced Cholangiocarcinoma","source_id_and_acronym":"NCT05823311","lead_sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • gemcitabine • Lenvima (lenvatinib) • Tevimbra (tislelizumab-jsgr)"],"overall_status":"Recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 09/01/2023","start_date":" 09/01/2023","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2027","study_completion_date":" 12/31/2027","last_update_posted":"2025-02-10"},{"id":"f87d079d-5408-46e1-abc8-978710f92fcc","acronym":"","url":"https://clinicaltrials.gov/study/NCT05532059","created_at":"2022-09-08T13:55:00.765Z","updated_at":"2025-02-25T15:27:37.097Z","phase":"Phase 2","brief_title":"Lenvatinib, Tislelizumab Plus Gemcitabine and Cisplatin (GPLET) in Patients with Advanced Cholangiocarcinoma","source_id_and_acronym":"NCT05532059","lead_sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • gemcitabine • Lenvima (lenvatinib) • Tevimbra (tislelizumab-jsgr)"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 01/31/2022","start_date":" 01/31/2022","primary_txt":" Primary completion: 08/31/2025","primary_completion_date":" 08/31/2025","study_txt":" Completion: 08/31/2028","study_completion_date":" 08/31/2028","last_update_posted":"2025-02-10"},{"id":"1c396f9f-301a-4705-afde-65c99cd26512","acronym":"LIBRETTO-321","url":"https://clinicaltrials.gov/study/NCT04280081","created_at":"2021-01-18T20:46:57.085Z","updated_at":"2025-02-25T16:32:06.121Z","phase":"Phase 2","brief_title":"A Study of Selpercatinib (LY3527723) in Participants With Advanced Solid Tumors Including RET Fusion-positive Solid Tumors, Medullary Thyroid Cancer and Other Tumors With RET Activation","source_id_and_acronym":"NCT04280081 - LIBRETTO-321","lead_sponsor":"Eli Lilly and Company","biomarkers":" RET","pipe":" | ","alterations":" RET mutation","tags":["RET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RET mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Retevmo (selpercatinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 77","initiation":"Initiation: 03/16/2020","start_date":" 03/16/2020","primary_txt":" Primary completion: 03/25/2021","primary_completion_date":" 03/25/2021","study_txt":" Completion: 11/01/2027","study_completion_date":" 11/01/2027","last_update_posted":"2025-02-07"},{"id":"e3328e0d-a58a-4276-b607-b9374b9c681f","acronym":"AcceleRET Lung","url":"https://clinicaltrials.gov/study/NCT04222972","created_at":"2021-01-18T14:26:40.385Z","updated_at":"2025-02-25T16:37:43.151Z","phase":"Phase 3","brief_title":"A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)","source_id_and_acronym":"NCT04222972 - AcceleRET Lung","lead_sponsor":"Hoffmann-La Roche","biomarkers":" RET","pipe":" | ","alterations":" RET fusion","tags":["RET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RET fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cisplatin • carboplatin • gemcitabine • albumin-bound paclitaxel • pemetrexed • Gavreto (pralsetinib)"],"overall_status":"Completed","enrollment":" Enrollment 223","initiation":"Initiation: 07/24/2020","start_date":" 07/24/2020","primary_txt":" Primary completion: 01/27/2025","primary_completion_date":" 01/27/2025","study_txt":" Completion: 01/27/2025","study_completion_date":" 01/27/2025","last_update_posted":"2025-02-06"},{"id":"f5cb8c43-6865-4b75-b3de-bf63f4e8a4e4","acronym":"LEAP-015","url":"https://clinicaltrials.gov/study/NCT04662710","created_at":"2021-01-19T20:42:39.419Z","updated_at":"2025-02-25T13:35:41.688Z","phase":"Phase 3","brief_title":"Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) Plus Chemotherapy in Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-7902-015/E7080-G000-321/LEAP-015)","source_id_and_acronym":"NCT04662710 - LEAP-015","lead_sponsor":"Merck Sharp \u0026 Dohme LLC","biomarkers":" PD-L1","pipe":" | ","alterations":" HER-2 negative","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • 5-fluorouracil • Lenvima (lenvatinib) • capecitabine • oxaliplatin • leucovorin calcium • levoleucovorin calcium"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 895","initiation":"Initiation: 12/30/2020","start_date":" 12/30/2020","primary_txt":" Primary completion: 10/29/2024","primary_completion_date":" 10/29/2024","study_txt":" Completion: 03/31/2026","study_completion_date":" 03/31/2026","last_update_posted":"2025-02-06"},{"id":"0a783bcc-4ad7-4844-9ff8-1c57f587c024","acronym":"","url":"https://clinicaltrials.gov/study/NCT04759911","created_at":"2021-02-18T22:55:11.009Z","updated_at":"2025-02-25T16:53:32.021Z","phase":"Phase 2","brief_title":"Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancer","source_id_and_acronym":"NCT04759911","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" RET","pipe":"","alterations":" ","tags":["RET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Retevmo (selpercatinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 02/26/2021","start_date":" 02/26/2021","primary_txt":" Primary completion: 11/30/2025","primary_completion_date":" 11/30/2025","study_txt":" Completion: 11/30/2025","study_completion_date":" 11/30/2025","last_update_posted":"2025-02-04"},{"id":"fc12ec5e-bd90-482d-9d25-a68cd6f10bca","acronym":"LIBRETTO-531","url":"https://clinicaltrials.gov/study/NCT04211337","created_at":"2021-01-18T20:30:33.890Z","updated_at":"2025-02-25T16:52:48.085Z","phase":"Phase 3","brief_title":"A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer","source_id_and_acronym":"NCT04211337 - LIBRETTO-531","lead_sponsor":"Loxo Oncology, Inc.","biomarkers":" RET","pipe":" | ","alterations":" RET mutation","tags":["RET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RET mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Cabometyx (cabozantinib tablet) • Retevmo (selpercatinib) • Caprelsa (vandetanib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 291","initiation":"Initiation: 02/11/2020","start_date":" 02/11/2020","primary_txt":" Primary completion: 05/22/2023","primary_completion_date":" 05/22/2023","study_txt":" Completion: 02/01/2026","study_completion_date":" 02/01/2026","last_update_posted":"2025-02-04"},{"id":"739976b0-7ec7-4952-93a7-789eca0ef355","acronym":"","url":"https://clinicaltrials.gov/study/NCT05114421","created_at":"2021-11-10T14:12:47.360Z","updated_at":"2025-02-25T17:25:20.145Z","phase":"Phase 2","brief_title":"Pembrolizumab and Lenvatinib for the Treatment of Serous Ovarian Cancer Patients","source_id_and_acronym":"NCT05114421","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Lenvima (lenvatinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 11/09/2021","start_date":" 11/09/2021","primary_txt":" Primary completion: 01/31/2026","primary_completion_date":" 01/31/2026","study_txt":" Completion: 01/31/2026","study_completion_date":" 01/31/2026","last_update_posted":"2025-01-31"},{"id":"7ad02231-e51d-4e77-bde9-f01924b1ddec","acronym":"PELICAN","url":"https://clinicaltrials.gov/study/NCT06232564","created_at":"2024-01-30T19:21:28.994Z","updated_at":"2025-02-25T17:32:47.858Z","phase":"Phase 2","brief_title":"A Study of Etoposide-carboplatin in Combination With Pembrolizumab and Lenvatinib Maintenance in HG-NETs","source_id_and_acronym":"NCT06232564 - PELICAN","lead_sponsor":"Imperial College London","biomarkers":" PD-1 • VEGFA • CD34 • FOXP3","pipe":"","alterations":" ","tags":["PD-1 • VEGFA • CD34 • FOXP3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • carboplatin • Lenvima (lenvatinib) • etoposide IV"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 07/08/2024","start_date":" 07/08/2024","primary_txt":" Primary completion: 03/02/2028","primary_completion_date":" 03/02/2028","study_txt":" Completion: 08/02/2028","study_completion_date":" 08/02/2028","last_update_posted":"2025-01-30"},{"id":"903e5cab-7626-44c4-a016-54d2f4cf78c1","acronym":"LIBRETTO-431","url":"https://clinicaltrials.gov/study/NCT04194944","created_at":"2021-01-18T20:26:38.725Z","updated_at":"2025-02-25T17:30:06.532Z","phase":"Phase 3","brief_title":"A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT04194944 - LIBRETTO-431","lead_sponsor":"Eli Lilly and Company","biomarkers":" RET","pipe":" | ","alterations":" RET fusion","tags":["RET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RET fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cisplatin • carboplatin • Retevmo (selpercatinib) • pemetrexed"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 261","initiation":"Initiation: 02/17/2020","start_date":" 02/17/2020","primary_txt":" Primary completion: 05/01/2023","primary_completion_date":" 05/01/2023","study_txt":" Completion: 06/01/2026","study_completion_date":" 06/01/2026","last_update_posted":"2025-01-30"},{"id":"d09ef236-9ffc-468c-9ac9-80033eba5a47","acronym":"","url":"https://clinicaltrials.gov/study/NCT05147558","created_at":"2021-12-07T13:53:36.843Z","updated_at":"2025-02-25T16:17:01.717Z","phase":"Phase 2","brief_title":"A Study of Pembrolizumab With Lenvatinib in Women With Advanced Uterine Carcinosarcoma","source_id_and_acronym":"NCT05147558","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" MSI","pipe":" | ","alterations":" MSI-H/dMMR","tags":["MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Lenvima (lenvatinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 12/23/2021","start_date":" 12/23/2021","primary_txt":" Primary completion: 12/23/2025","primary_completion_date":" 12/23/2025","study_txt":" Completion: 12/23/2025","study_completion_date":" 12/23/2025","last_update_posted":"2025-01-27"},{"id":"6d8ce925-047e-4380-9392-20b7805d056d","acronym":"","url":"https://clinicaltrials.gov/study/NCT04955743","created_at":"2021-07-09T12:57:14.611Z","updated_at":"2025-02-25T16:16:25.608Z","phase":"Phase 2","brief_title":"Pembrolizumab and Lenvatinib in Patients With Brain Metastases From Melanoma or Renal Cell Carcinoma","source_id_and_acronym":"NCT04955743","lead_sponsor":"Yale University","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF mutation","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Lenvima (lenvatinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 56","initiation":"Initiation: 02/09/2022","start_date":" 02/09/2022","primary_txt":" Primary completion: 01/31/2027","primary_completion_date":" 01/31/2027","study_txt":" Completion: 01/31/2027","study_completion_date":" 01/31/2027","last_update_posted":"2024-12-24"},{"id":"05e655b5-ceb5-4cfa-ba00-4d49783fd7fb","acronym":"LEAP-003","url":"https://clinicaltrials.gov/study/NCT03820986","created_at":"2021-01-18T18:52:34.602Z","updated_at":"2025-02-25T13:35:12.099Z","phase":"Phase 3","brief_title":"Safety and Efficacy Study of Pembrolizumab (MK-3475) Combined With Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Advance Melanoma (MK-7902-003/E7080-G000-312/LEAP-003)","source_id_and_acronym":"NCT03820986 - LEAP-003","lead_sponsor":"Merck Sharp \u0026 Dohme LLC","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF mutation • BRAF V600 • BRAF wild-type","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF V600 • BRAF wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Lenvima (lenvatinib)"],"overall_status":"Completed","enrollment":" Enrollment 674","initiation":"Initiation: 03/12/2019","start_date":" 03/12/2019","primary_txt":" Primary completion: 01/18/2023","primary_completion_date":" 01/18/2023","study_txt":" Completion: 11/01/2024","study_completion_date":" 11/01/2024","last_update_posted":"2024-12-02"},{"id":"619fd7c9-dbb3-4095-b877-184ef406df55","acronym":"LEAP-003 China Extension","url":"https://clinicaltrials.gov/study/NCT04889118","created_at":"2021-05-17T18:56:08.830Z","updated_at":"2025-02-25T13:35:49.940Z","phase":"Phase 3","brief_title":"Safety and Efficacy Study of Pembrolizumab (MK-3475) Combined With Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Advanced Melanoma (MK-7902-003/E7080-G000-312/LEAP-003)-China Extension Study","source_id_and_acronym":"NCT04889118 - LEAP-003 China Extension","lead_sponsor":"Merck Sharp \u0026 Dohme LLC","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF mutation • BRAF V600 • BRAF wild-type","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF V600 • BRAF wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Lenvima (lenvatinib)"],"overall_status":"Completed","enrollment":" Enrollment 131","initiation":"Initiation: 07/14/2020","start_date":" 07/14/2020","primary_txt":" Primary completion: 01/18/2023","primary_completion_date":" 01/18/2023","study_txt":" Completion: 11/01/2024","study_completion_date":" 11/01/2024","last_update_posted":"2024-12-02"},{"id":"6e09028c-351c-49a3-ae4b-ecc4e168b4c6","acronym":"","url":"https://clinicaltrials.gov/study/NCT04267120","created_at":"2021-01-18T20:44:00.448Z","updated_at":"2025-02-25T16:10:00.555Z","phase":"Phase 2","brief_title":"Lenvatinib (LEN) in Combination With Pembrolizumab (KEYtruda) in Subjects With Locally Advanced or Metastatic Non-clear Cell Renal Cell Carcinoma (The LENKYN Trial)","source_id_and_acronym":"NCT04267120","lead_sponsor":"Washington University School of Medicine","biomarkers":" SDHB • TSC1","pipe":" | ","alterations":" TSC1 deletion","tags":["SDHB • TSC1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TSC1 deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Lenvima (lenvatinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 11","initiation":"Initiation: 07/29/2020","start_date":" 07/29/2020","primary_txt":" Primary completion: 07/09/2024","primary_completion_date":" 07/09/2024","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-11-26"},{"id":"26ce8992-3a8f-449a-80fd-e840f4035ed9","acronym":"AMBER","url":"https://clinicaltrials.gov/study/NCT06068153","created_at":"2023-10-05T16:11:10.857Z","updated_at":"2025-02-25T13:36:28.930Z","phase":"Phase 2","brief_title":"AMG510 (sotorasib) Plus Lenvatinib As Second-line Treatment in Patients with KRASG12C Mutant, Metastatic NSCLC","source_id_and_acronym":"NCT06068153 - AMBER","lead_sponsor":"ETOP IBCSG Partners Foundation","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • KRAS G12C • KRAS G12","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12C • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lenvima (lenvatinib) • Lumakras (sotorasib)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 03/01/2025","start_date":" 03/01/2025","primary_txt":" Primary completion: 09/30/2026","primary_completion_date":" 09/30/2026","study_txt":" Completion: 12/30/2026","study_completion_date":" 12/30/2026","last_update_posted":"2024-11-20"},{"id":"17df3b54-8527-4d38-a58f-5e18bf2e1770","acronym":"","url":"https://clinicaltrials.gov/study/NCT06110793","created_at":"2023-11-01T15:12:25.826Z","updated_at":"2025-02-25T16:19:14.320Z","phase":"Phase 1/2","brief_title":"A Study of Lenvatinib, Pembrolizumab, and Fulvestrant in People With Breast Cancer","source_id_and_acronym":"NCT06110793","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Lenvima (lenvatinib) • fulvestrant"],"overall_status":"Recruiting","enrollment":" Enrollment 43","initiation":"Initiation: 12/29/2023","start_date":" 12/29/2023","primary_txt":" Primary completion: 11/01/2026","primary_completion_date":" 11/01/2026","study_txt":" Completion: 11/01/2026","study_completion_date":" 11/01/2026","last_update_posted":"2024-11-18"},{"id":"9ef28cb0-6b0e-4242-8ea3-6de25a48faed","acronym":"LEAP-008","url":"https://clinicaltrials.gov/study/NCT03976375","created_at":"2021-01-18T19:33:26.274Z","updated_at":"2025-02-25T13:35:24.264Z","phase":"Phase 3","brief_title":"Efficacy and Safety of Pembrolizumab (MK-3475) With Lenvatinib (E7080/MK-7902) vs. Docetaxel in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease (PD) After Platinum Doublet Chemotherapy and Immunotherapy (MK-7902-008/E7080-G000-316/LEAP-008)","source_id_and_acronym":"NCT03976375 - LEAP-008","lead_sponsor":"Merck Sharp \u0026 Dohme LLC","biomarkers":" EGFR • KRAS • ALK • ROS1","pipe":" | ","alterations":" KRAS mutation • EGFR L858R • ALK rearrangement • RAS mutation","tags":["EGFR • KRAS • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • EGFR L858R • ALK rearrangement • RAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • docetaxel • Lenvima (lenvatinib)"],"overall_status":"Completed","enrollment":" Enrollment 422","initiation":"Initiation: 06/26/2019","start_date":" 06/26/2019","primary_txt":" Primary completion: 08/11/2023","primary_completion_date":" 08/11/2023","study_txt":" Completion: 08/22/2024","study_completion_date":" 08/22/2024","last_update_posted":"2024-11-18"}]